Alnylam Pharma (ALNY) Tops Q1 EPS by 35c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $286.41 +2.99%
Revenue Growth %: +70.6%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +70.6%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.49), $0.35 better than the analyst estimate of ($1.84). Revenue for the quarter came in at $213.26 million versus the consensus estimate of $243.02 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Accenture downgraded by TD Cowen on AI concerns
- Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
